JPRN-jRCT2080222886未知3 期
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Phase 3 Long-term Study to Evaluate Efficacy and Safety of 12 Weeks and 52 Weeks of AZD0585 Administration, Respectively, in Japanese Patients With Hyperlipidemia Accompanied by Hypertriglyceridemia.
适应症
试验速览
- 阶段
- 3 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Subjects must meet all of the following criteria;
- •a. Fasting triglyceride level: average of Visit 2 and Visit 3 must be in the range 150 - 499 mg/dL
- •b. %TG change between Visit 2 and Visit 3 must be within 30%
- •c. %LDL-C change between Visit 2 and Visit 3 must be within 25%
排除标准
- •- Allergy or intolerance to omega-3 fatty acids and omega-3-acid ethyl esters.
- •- Known lipoprotein lipase impairment or deficiency, or Apolipoprotein C-2 deficiency or familial dysbetalipoproteinemia.
- •- Current or history of pancreatitis.
- •- Type 1 diabetes mellitus, use of insulin, or haemoglobin A1c >10% at Visit 1.
研究者
相似试验
已完成
3 期
Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS) (MERIT)JPRN-jRCT2031200306Sugiyama Yutaro160
已完成
不适用
Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.-J45J45PER-024-08GLAXOSMITHKLINE PERU S.A.,
进行中（未招募）
1 期
Phase 2 study to evaluate the efficacy and safety of a ten-days treament of subjects with peripheral post-surgical neuropathic pain with drug AP-325 or placeboPeripheral post-surgical neuropathic painMedDRA version: 20.0Level: LLTClassification code 10077974Term: Peripheral neuropathic painSystem Organ Class: 100000004852EUCTR2019-003502-28-ESAlgiax Pharmaceuticals GmbH94
进行中（未招募）
1 期
Phase 2 study to evaluate the efficacy and safety of a ten-days treament of subjects with peripheral post-surgical neuropathic pain with drug AP-325 or placeboEUCTR2019-003502-28-CZAlgiax Pharmaceuticals GmbH94
进行中（未招募）
1 期
Phase 2 study to evaluate the efficacy and safety of a ten-days treament of subjects with peripheral post-surgical neuropathic pain with drug AP-325 or placeboPeripheral post-surgical neuropathic painMedDRA version: 20.0Level: LLTClassification code 10077974Term: Peripheral neuropathic painSystem Organ Class: 100000004852EUCTR2019-003502-28-DEAlgiax Pharmaceuticals GmbH96